Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.17 - $0.37 $28,492 - $62,012
-167,600 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$0.33 - $0.42 $47,322 - $60,228
-143,400 Reduced 46.11%
167,600 $62,000
Q4 2021

Feb 11, 2022

SELL
$0.36 - $0.77 $10,944 - $23,408
-30,400 Reduced 8.9%
311,000 $110,000
Q3 2021

Nov 12, 2021

BUY
$0.59 - $0.88 $135,936 - $202,752
230,400 Added 207.57%
341,400 $256,000
Q2 2021

Aug 13, 2021

BUY
$0.83 - $1.14 $92,130 - $126,539
111,000 New
111,000 $97,000
Q3 2020

Nov 13, 2020

SELL
$0.34 - $0.55 $6,143 - $9,937
-18,069 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$0.42 - $1.44 $13,564 - $46,507
-32,297 Reduced 64.12%
18,069 $9,000
Q4 2019

Feb 13, 2020

SELL
$0.77 - $1.08 $21,087 - $29,577
-27,387 Reduced 35.22%
50,366 $46,000
Q3 2019

Nov 13, 2019

SELL
$1.0 - $2.97 $15,516 - $46,082
-15,516 Reduced 16.64%
77,753 $80,000
Q2 2019

Aug 12, 2019

SELL
$2.04 - $5.43 $34,290 - $91,272
-16,809 Reduced 15.27%
93,269 $275,000
Q1 2019

May 14, 2019

BUY
$3.03 - $4.65 $233,309 - $358,050
77,000 Added 232.78%
110,078 $512,000
Q4 2018

Feb 13, 2019

BUY
$1.3 - $3.87 $43,001 - $128,011
33,078 New
33,078 $97,000

About Aeterna Zentaris Inc.


  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.